Graft-versus-host disease
Graft-versus-host disease |
Differentiating Graft-versus-host disease from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Graft-versus-host disease On the Web |
American Roentgen Ray Society Images of Graft-versus-host disease |
Risk calculators and risk factors for Graft-versus-host disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: GVHD
Overview
Graft-versus-host disease (GvHD) is a condition characterized by recipient tissue damage that arise from immunological activation of donor T lymphocytes. It typically occurs in the setting of bone marrow transplantation. Donor T cells mount a response against foreign host cells in the gastrointestinal system, liver, and skin.
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Graft-versus-host disease from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy Ruxolitinib has been used for GvHD that is refractory to steroids.[1]
| Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related Chapters
- ↑ Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B (2017). "Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease". Br J Haematol. doi:10.1111/bjh.14679. PMID 28444730.